Fig 1.
Trend in relapse as a proportion of visceral leishmaniasis (VL) cases treated at Médecins Sans Frontières (MSF) centre in Lankien, South Sudan, 2001–2018 (from programme monitoring data)*.
* Join-point analyses indicated that the best-fit (log linear) model had zero join points and an annual percent change in relapse as a proportion of all VL cases from 2001 to 2018 of 6.5% (95% CI 0.3% to 13.0%, p = 0.04).
Table 1.
Primary and relapse visceral leishmaniasis (VL) cases as proportions of all VL patients treated at Médecins Sans Frontières (MSF) centre in Lankien, South Sudan, 2001–2018 (from programme monitoring data).
Fig 2.
Flow of routinely-collected patient-level data from clinical records.
Table 2.
Characteristics of primary visceral leishmaniasis (VL) and VL relapse patients treated at Médecins Sans Frontières (MSF) centres in South Sudan, 2001–2018 (patient-level data on admission).
Table 3.
Treatment of visceral leishmaniasis (VL) patients and time to relapse at Médecins Sans Frontières (MSF) centres in South Sudan, 2001–2018 (from patient-level data).
Table 4.
Spleen size (distance in centimetres from left costal margin to tip of spleen) on admission and discharge for primary and relapse visceral leishmaniais (VL) patients at Médecins Sans Frontières (MSF) centres in South Sudan, 2014–2018 (from patient-level data).